OTCMKTS:BMXMFBioMerieux Stock Price, Forecast & News

$134.00

+3.55 (+2.72 %)

(As of 06/4/2020 04:00 PM ET)

Add

Compare

Today's Range

$134.00

Now: $134.00▼

$134.00

50-Day Range

$111.50

MA: $131.40▼

$147.43

52-Week Range

$75.70

Now: $134.00▼

$148.30

Volume8 shs

Average VolumeN/A

Market Capitalization$15.86 billion

P/E Ratio51.94

Dividend YieldN/A

BetaN/A

bioMérieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company offers microbiology technology that involves culturing biological samples; and immunoassays technology based on antigen-antibody reaction, detects and measures infectious agents, such as bacteria, viruses, and parasites, as well as measures the specific biomarkers of various pathologies, such as metabolic, hormonal, infectious, etc. It also provides molecular biology for the detection of genetic sequences of deoxyribonucleic acid or ribonucleic acid; and companion diagnostic test based on biomarkers, as well as services for clinical and industrial laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is based in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for BioMerieux.

2.5 Community Rank

Outperform Votes
BioMerieux has received 98 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
BioMerieux has received 98 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
BioMerieux has received 50.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about BioMerieux and other stocks. Vote “Outperform” if you believe BMXMF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BMXMF will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
BioMerieux does not currently pay a dividend.
Dividend Growth
BioMerieux does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioMerieux insiders have not sold or bought any company stock.

0.6 Earnings and Valuation

Earnings Growth
Earnings for BioMerieux are expected to grow by 12.59% in the coming year, from $2.78 to $3.13 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BioMerieux is 51.94, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.96.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioMerieux is 51.94, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.64.
Price to Book Value per Share Ratio
BioMerieux has a P/B Ratio of 6.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.63 out of 5 stars

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Private households

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:BMXMF

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.biomerieux.com

Phone33-4-78-87-20-00

Debt

Debt-to-Equity Ratio0.07

Current Ratio1.23

Quick Ratio0.81

Price-To-Earnings

Trailing P/E Ratio51.94

Forward P/E Ratio48.20

P/E GrowthN/A

Sales & Book Value

Annual Sales$3.00 billion

Price / Sales5.29

Cash FlowN/A

Price / Cash FlowN/A

Book Value$21.33 per share

Price / Book6.28

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees12,000

Outstanding Shares118,360,000

Market Cap$15.86 billion

Next Earnings Date6/10/2020 (Estimated)

OptionableNot Optionable

Receive BMXMF News and Ratings via Email

Sign-up to receive the latest news and ratings for BMXMF and its competitors with MarketBeat's FREE daily newsletter.

BioMerieux (OTCMKTS:BMXMF) Frequently Asked Questions

How has BioMerieux's stock been impacted by COVID-19 (Coronavirus)?

BioMerieux's stock was trading at $91.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BMXMF stock has increased by 46.4% and is now trading at $134.00. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of BioMerieux?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMerieux in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for BioMerieux.

When is BioMerieux's next earnings date?

BioMerieux is scheduled to release its next quarterly earnings announcement on Wednesday, June 10th 2020. View our earnings forecast for BioMerieux.

Has BioMerieux been receiving favorable news coverage?

News coverage about BMXMF stock has been trending extremely negative on Friday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BioMerieux earned a daily sentiment score of -5.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutBioMerieux.

Who are some of BioMerieux's key competitors?

Some companies that are related to BioMerieux include Aurora Cannabis (ACBFF), Carillion (CIOIF), Constellation Software (CNSWF), Countrywide (CYWDF), Cybg (CBBYF), Debenhams (DBHSY), Enquest (ENQUF), Hitachi Kokusai Electric (HTKKY), HOPEWELL HOLDIN/ADR (HOWWY), IQE (IQEPF), Pax Global Technology (PXGYF), Purplebricks Group (PRPPF), SOCO International (SOCLF), SSP GROU/PAR VTG FPD 0.01033333 (SSPPF) and THOMAS COOK GRP/ADR (TCKGY). View all competitors.

Who are BioMerieux's key executives?

BioMerieux's management team includes the following people:

Mr. Alexandre Mérieux, Chairman & CEO (Age 45)
Mr. Guillaume Bouhours, Exec. VP and Exec. VP of Fin., Purchasing & Information Systems (Age 43)
Sylvain Morgeau, Investor Relations
Ms. Valérie Leyldé, Exec. VP of HR and Communications
Mr. Michel Baguenault, Exec. VP & Company Sec.

What is BioMerieux's stock symbol?

BioMerieux trades on the OTCMKTS under the ticker symbol "BMXMF."

How do I buy shares of BioMerieux?

Shares of BMXMF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioMerieux's stock price today?

One share of BMXMF stock can currently be purchased for approximately $134.00.

How big of a company is BioMerieux?

BioMerieux has a market capitalization of $15.86 billion and generates $3.00 billion in revenue each year. The company earns $305.54 million in net income (profit) each year or $2.58 on an earnings per share basis. BioMerieux employs 12,000 workers across the globe.

What is BioMerieux's official website?

The official website for BioMerieux is www.biomerieux.com.

How can I contact BioMerieux?

BioMerieux's mailing address is 376 Chemin De l`Orme, Marcy l`Etoile I0, 69280. The company can be reached via phone at 33-4-78-87-20-00 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff